We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Electroporation Device Helps Kill Cancer Cells

By HospiMedica International staff writers
Posted on 06 Nov 2012
A novel device causes pores in the membrane of cancer cells to open, thus significantly increasing the uptake of anticancer agents. More...


The OncoSec electroporation device is intended for use during chemotherapy and immunotherapy to open pores within the membranes of target cancer cells, making them more susceptible to injected compounds, thus improving therapy effectiveness and reducing systemic toxicity. The electroporation platform consists of a generator that creates a pulsed electric field that temporarily increases the porosity of cell membranes within the treatment field. A hand-held applicator then supplies a series of short-duration electrical pulses of specific voltage through a series of needles.

Together, the action of the generator and applicator creates a rotating array of pulses that uniformly subject the targeted cell membranes to electroporation. The electric fields generated are inert, and dissipate once the device is stopped, reducing concerns about residual long-term effects. Results from the phase I study have demonstrated that only one week of treatment could result in clinical benefit for late-stage cancer patients. The OncoSec electroporation device is a product of OncoSec Medical System (OMS; San Diego, CA, USA), and has received the European Community CE marking of approval.

“We strongly believe in the clinical relevance of our therapeutic approach,” said Said Punit Dhillon, president and CEO of OncoSec. “Clinical experience […] supports the uniqueness of OMS ElectroChemotherapy in its ability to achieve selective destruction of cancerous tumors while sparing healthy normal tissue including highly vascularized and innervated surrounding structures, providing physicians with an important flexible treatment alternative.”

The electroporation device currently works with two anticancer therapies: ImmunoPulse, which delivers instructions to the cell to deliver a DNA-based cytokine coded for the immune stimulating agent interleukin-12 (DNA IL-12), which induces a cytokine cascade with antiangiogenic effects; and NeoPulse, which delivers bleomycin, an approved anticancer drug that specifically targets and destroys cancer cells.

Related Links:

OncoSec Medical System




Gold Member
12-Channel ECG
CM1200B
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Digital Radiography System (Ceiling Free)
Digix CF Series
New
Pediatric Mask
Respire SOFT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The new Cora Torqueable Microcatheters expand our coronary portfolio supporting patients with coronary artery disease (photo courtesy of Reflow Medical)

Torqueable Microcatheters Enhance Navigation in Complex Coronary Lesions

Interventional cardiologists frequently encounter tortuous vessels and heavily calcified or fibrotic coronary lesions that complicate guidewire control and device delivery. Stable, predictable torque and... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.